Navigation Links
Alliqua Strengthens and Realigns Executive Team
Date:2/5/2013

NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or the "Company") today announced a strategic realignment of the senior executive team. This change is designed to strengthen the leadership of the Company's differentiated businesses including the sales of Alliqua's marketed brands, SilverSeal® and Hydress®. The Alliqua Board of Directors has approved David Johnson , who joined the Board in December of 2012 and is currently the executive chairman of AquaMed Technologies, to now assume the additional responsibility of chief executive officer of Alliqua, Inc. Concurrently, James Sapirstein will become the chief executive officer of Alliqua BioMedical, Inc., a wholly-owned subsidiary of the Company. 

"David is an excellent choice to take on these additional responsibilities, with his deep background in leading world class organizations, most recently Convatec Inc., a $1.7 billion global leader in wound therapeutic technologies; and will position the company well to build value for our shareholders," said Jerome Zeldis , M.D., Ph.D., chairman of the Alliqua Board of Directors. "Under James Sapirstein's leadership as CEO, Alliqua has adopted a new a strategic corporate plan including a process to bolstering our proprietary product pipeline. His skills and counsel will continue to be valuable to Alliqua as we move forward and take the next step by realigning our leadership team to best support our business."

"In the two months since I joined Alliqua, it has become apparent that great opportunities exist for both the immediate commercialization of our existing wound care products, SilverSeal® and Hydress®, as well as our platform hydrogel technology," said Dave Johnson . "In addition, we will continue to pursue opportunistic ways to expand our technology platforms to better serve our customers and to expand into new therapeutic areas."

James Sapirstein added, "As the chief executive of Alliqua BioMedical, we will focus on the expansion of Alliqua's proprietary product line by introducing new active pharmaceutical ingredients into our hydrogel technology for the topical delivery of local and systemic therapies. By doing so, we may realize the significant potential of our Company's hydrogel technology."

About Alliqua, Inc.

Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies. Alliqua's leading technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.

Alliqua currently markets its new line of 510K FDA-approved hydrogel products for wound care under the SilverSeal® brand. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne PA, allows Alliqua to aggressively develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. Additionally, Alliqua's drug delivery platform, in combination with certain active pharmaceutical ingredients, can provide pharmaceutical companies with a transdermal technology to enhance patient compliance and potentially extend the patent life of valuable drug franchises. Additionally, our subsidiary, HepaLife Biosystems, Inc., focuses on the development of a cell-based bioartificial liver system, known as HepaMate™.

For additional information, please visit www.alliqua.com. To receive future press releases via email, please visit: http://alliqua.com/contacts.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward- looking statements as a result of new information, future events or otherwise.

Contacts for Alliqua, Inc.
Steven Berger
Chief Financial Officer
646-218-1450 
info@alliqua.com 


'/>"/>
SOURCE Alliqua, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alliqua Names David Johnson Executive Chairman of Aquamed Technologies and Member of Alliqua Board of Directors
2. Alliqua to Explore Business Development Efforts for Hydrogel Transdermal Delivery Platform in the Cosmeceutical Industry
3. Alliqua Appoints Dr. Joseph Laudano as Vice President of Medical Affairs to Support the Market Expansion of Alliquas SilverSeal Products and Future Clinical Development
4. inVentiv Health Strengthens Clinical Leadership Team
5. Jardogs Strengthens Leadership Team with the Addition of Two Seasoned Healthcare Executives
6. Pharmalink AB Strengthens Senior Management Team
7. Actinium Pharmaceuticals Strengthens Management Team
8. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
9. RxAlly Strengthens Leadership Team With New Chief Information Officer Mike Groh
10. Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals
11. CareFusion Strengthens U.K. Presence With Acquisition of Medical Products Distributor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 FinancialBuzz.com News Commentary  ... According to new ... market research, the legal cannabis market is projected to continue ... conflicting signals from the current presidential administration. The report created ... biggest drivers of growth in this industry are the passage ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... The IPF pipeline is very strong with a total of 97 ... Inc., Biogen and Sanofi are involved in the development of the IPF ... is in Phase III stage, 15 are in Phase II stage, 12 ...
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com ... has been growing rapidly as the global sales of Adcetris and ... growth in the antibody drug conjugates market is driven by large ... cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF ... the greater Houston Area. The new location is located at 2255 E. Mossy Oaks ... Springwoods Village. This newest location will provide patients living in the north Houston area ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
(Date:3/23/2017)... ... , ... The IoT (Internet of Things) is revolutionizing the way the world ... businesses and individual consumers alike. Laboratories can maximize their profit margin by increasing ... $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT ...
(Date:3/23/2017)... , ... March 23, 2017 , ... 82% of adults are unaware of the dangers ... not brush their teeth the minimum two times a day that dentists recommend. The ramifications ... 51 million hours of school and adults missing 164 million hours of work each year ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and thank ... Every day, two kidneys filter about 120 to 150 quarts of blood. Put another ... regulating fluid levels and blood pressure, supporting bone health and promoting red blood cell ...
Breaking Medicine News(10 mins):